Evidence map›Paper›PMID 27126396›Full record

ReviewHeart (British Cardiac Society)2016

Cardiovascular risk stratification in familial hypercholesterolaemia.

Mahtab Sharifi, Roby D Rakhit, Steve E Humphries, Devaki Nair

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Heart (British Cardiac Society), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 3 pooled it
9.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 3 syntheses or guidelines pooled it, 75 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Observational
  10. Review
  11. Review
  12. 2023 China Guidelines for Lipid Management.Journal of geriatric cardiology : JGC · 2023
    Article
  13. 2023 Chinese guideline for lipid management.Frontiers in pharmacology · 2023
    Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Mahtab SharifiDepartment of Clinical Biochemistry, Royal Free Hospital, London, UK Department of Cardiology, Royal Free Hospital and Institute of Cardiovascular Science, University College London, London, UK Cardiovascular Genetic Centre, University College London, London, UK.
Roby D RakhitDepartment of Cardiology, Royal Free Hospital and Institute of Cardiovascular Science, University College London, London, UK.
Steve E HumphriesCardiovascular Genetic Centre, University College London, London, UK.
Devaki NairDepartment of Clinical Biochemistry, Royal Free Hospital, London, UK.
The Royal Free Hospital · GBRoyal London Hospital · GBUniversity College London · GB

Funding

British Heart Foundation RG/08/008/25291
6 · The paper itself

Abstract

Familial hypercholesterolaemia (FH) is a common autosomal-dominant disorder in most European countries. Patients with FH are characterised by a raised level of low-density lipoprotein cholesterol and a high risk of premature coronary heart disease (CHD). Currently there is no consensus regarding the clinical utility to predict future coronary events or testing for the presence of subclinical atherosclerotic disease in asymptomatic patients with FH. Family screening of patients with FH as recommended by the UK National Institute of Health and Care Excellence guideline would result in finding many young individuals with a diagnosis of FH who are clinically asymptomatic. The traditional CHD risk scores, that is, the Framingham score, are insufficient in risk prediction in this group of young individuals. In addition, a better understanding of the genetic aetiology of the FH phenotype and CHD risk in monogenic FH and polygenic hypercholesterolaemia is needed. Non-invasive imaging methods such as carotid intima-media thickness measurement might produce more reliable information in finding high-risk patients with FH. The potential market authorisation of novel therapeutic agents such as PCSK9 monoclonal inhibitors makes it essential to have a better screening programme to prioritise the candidates for treatment with the most severe form of FH and at higher risk of coronary events. The utility of new imaging techniques and new cardiovascular biomarkers remains to be determined in prospective trials.

Indexed as

Cardiovascular DiseasesGenetic Predisposition to DiseaseHumansHyperlipoproteinemia Type IIMagnetic Resonance ImagingRisk AssessmentRisk FactorsTomography, X-Ray Computed

Identifiers

PMID27126396
PMCPMC4941166
OpenAlexW2342816298

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.